According to Lupin, the MHRA has approved company’s Lutio tiotropium bromide inhalation powder, a generic version of Boehringer Ingelheim’s Spiriva Handihaler. The approval is the second for a Lupin OINDP in the UK; the MHRA approved the company’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD, a generic of Chiesi’s Fostair, in June 2021, and Lupin launched Luforbec in the UK in August 2021.
Lupin President, EMEA, Thierry Volle commented, “We are pleased to have received the approval of Lutio from the MHRA for the treatment of chronic obstructive pulmonary disease (COPD), providing an effective and high-quality treatment option to patients in UK.”
Read the Lupin press release.
